Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study

Gastroenterology

Volumn 128, Issue 7, 2005, Pages 1805-1811

  Järnerot, Gunnar ^a   Hertervig, Erik ^b   Friis Liby, Ingalill ^c   Blomquist, Lars ^d   Karlén, Per ^e   Grännö, Christer ^f   Vilien, Mogens ^g   Ström, Magnus ^h   Danielsson, Åke ⁱ   Verbaan, Hans ^b   Hellström, Per M ^d   Magnuson, Anders ^a   Curman, Bengt ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e STOCKHOLM SÖDER HOSPITAL   (Sweden)

^f RYHOV COUNTY HOSPITAL   (Sweden)

^g SLAGELSE HOSPITAL   (Denmark)

^h LINKÖPING UNIVERSITY   (Sweden)

ⁱ UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BETAMETHASONE; CORTICOSTEROID; INFLIXIMAB; PLACEBO; PREDNISOLONE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; COLON RESECTION; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ERUPTION; DRUG SAFETY; EPIGASTRIC PAIN; FEMALE; FEVER; FLUSHING; GASTROINTESTINAL REFLUX; HEADACHE; HUMAN; HYPERHIDROSIS; KNEE PAIN; LIVER FUNCTION TEST; MALE; MORTALITY; NAUSEA; OPPORTUNISTIC INFECTION; PNEUMONIA; PNEUMOTHORAX; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PRURITUS; PTOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM HEMORRHAGE; SEPSIS; SEPTICEMIA; SINUS NODE; SKIN SENSATION; THRUSH; TREATMENT INDICATION; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

EID: 20444479336     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2005.03.003     Document Type: Article

References (26)

1. S.C. Truelove, D.P. Jewell Intensive intravenous regimen for severe attacks of ulcerative colitis Lancet 1 1974 1067 1070
2. G. Järnerot, P. Rolny, H. Sandberg-Gertzén Intensive intravenous treatment of ulcerative colitis Gastroenterology 89 1985 1005 1013
3. S. Lichtiger, D.H. Present, A. Kornbluth, I. Gelernt, J. Bauer, G. Galler, F. Michelassi, S. Hanauer Cyclosporine in severe ulcerative colitis refractory to steroid therapy N Engl J Med 330 1994 1841 1845
4. W.J. Sandborn A critical review of cyclosporine therapy in inflammatory bowel disease Inflamm Bowel Dis 1 1995 48 63
5. B. Blomberg, G. Järnerot Clinical evaluation and management of acute severe colitis Inflamm Bowel Dis 6 2000 214 227
6. J. Arts, G. D'Haens, M. Zeegers, G. van Assche, M. Hiele, A. D'Hoore, F. Penninckx, S. Vermeire, P. Rutgeerts Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis Inflamm Bowel Dis 10 2004 73 78
7. W.J. Sandborn, S.B. Hanauer Antitumor necrosis factor therapy for inflammatory bowel disease a review of agents, pharmacology, clinical results, and safety Inflamm Bowel Dis 5 1999 119 133
8. C.P. Braegger, S. Nicholls, S.H. Murch, S. Stephens, T.T. MacDonald Tumor necrosis factor alpha in stool as a marker of intestinal inflammation Lancet 339 1992 89 91
9. O.H. Nielsen, P. Gionchetti, M. Ainsworth, B. Vainer, M. Campieri, N. Borregaard, L. Kjeldsen Rectal dialysate and faecal concentrations of neutrophil gelatinase-associated lipocalin interleukin-8, and tumor necrosis factor-α in ulcerative colitis Am J Gastroenterol 94 1999 2923 2928
10. S.H. Murch, C.P. Braegger, J.A. Walker-Smith, T.T. MacDonald Location of tumor necrosis factor α by immunochemistry in chronic inflammatory bowel disease Gut 34 1993 1705 1709
11. A. Woywodt, D. Ludwig, P. Neustock, A. Kruse, K. Schwerting, G. Jantschek, H. Kirchner, E.F. Stange Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease Eur J Gastroenterol Hepatol 11 1999 267 276
12. M. Noguchi, N. Hiwatashi, Z. Lin, T. Toyota Secretion imbalance between tumor necrosis factor and its inhibition in inflammatory bowel disease Gut 43 1998 203 209
13. B.E. Sands, W.J. Tremaine, W.J. Sandborn, P.J. Rutgeerts, S.B. Hanauer, L. Mayer, L. Mayer, S. Targan, D.K. Podolsky Infliximab in the treatment of severe, steroid-refractory ulcerative colitis a pilot study Inflamm Bowel Dis 7 2001 83 88
14. W.Y. Chey, A. Hussain, C. Ryan, G.D. Potter, A. Shah Infliximab for refractory ulcerative colitis Am J Gastroenterol 96 2001 2373 2381
15. A. Kohu, C. Prantera, A. Pera, R. Cosintino, R. Sostegni, M. Daperno Anti-tumor necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis result of an open study on 13 patients Dig Liver Dis 34 2003 626 630
16. G. Järnerot, B. Blomberg, J. Bohr, B. Curman, H. Sandberg-Gertzén Infliximab (Remicade) as rescue therapy in acute corticosteroid-resistant ulcerative colitis Scand J Gastroenterol 36 Suppl 2001 233: 08.
17. M. Seo, M. Okada, T. Yao, M. Ueki, S. Arima, M. Okumura An index of disease activity in patients with ulcerative colitis Am J Gastroenterol 87 1992 971 976
18. S.C. Lindgren, L.M. Flood, A.F. Kilander, R. Löfberg, T.B. Persson, R.I. Sjödahl Early predictors of glucosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis Eur J Gastroenterol Hepatol 10 1998 831 835
19. F. Carbonnel, A. Lavergne, M. Lémann, A. Bitoun, P. Valleur, P. Hautefeuille, A. Galian, R. Modigliani, J.-C. Rambaud Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity Dig Dis Sci 39 1994 1550 1557
20. S.J. Pocock Clinical trials a practical approach 1983 Wiley Chichester 147-155
21. C.S.J. Probert, S.D. Hearing, S. Schreiber, T. Kühbacher, S. Ghosh, I.D.R. Arnott, A. Forbes Infliximab in moderately severe glucocorticoid resistant ulcerative colitis a randomised controlled trial Gut 52 2003 998 1002
22. F. Carbonnel, D. Gargouri, M. Lémann, L. Beaugerie, S. Cattan, J. Cosnes, J.P. Gendre Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis Aliment Pharmacol Ther 14 2000 273 279
23. J.-F. Colombel, E.V. Loftus, W.J. Tremaine, L.J. Egan, W.S. Harmsen, C.D. Schleck, A.R. Zinsmeister, W.J. Sandborn The safety profile of infliximab in patients with Crohn's disease the Mayo Clinic experience in 500 patients Gastroenterology 126 2004 19 31
24. T. Ljung, P. Karlén, D. Schmidt, P.M. Hellström, A. Lapidus, I. Janczewska, U. Sjökvist, R. Löfberg Infliximab in inflammatory bowel disease clinical outcome in a population based cohort from Stockholm County Gut 53 2004 849 853
25. L. Marchal, G. D'Haens, G. van Assche, S. Vermeire, M. Noman, M. Ferrante, M. Hiele, M. Bueno de Mesquita, A. D'Hoore, F. Pennickx, P. Rutgeerts The risk of post-operative complications associated with infliximab therapy for Crohn's disease a controlled cohort study Aliment Pharmacol Ther 19 2004 749 754
26. S.P.L. Travis, J.M. Farrant, C. Ricketts, D.J. Nolan, N.M. Mortensen, M.G.N. Kettlewell, D.P. Jewell Predicting outcome in severe ulcerative colitis Gut 38 1996 905 910